We are live on ! Find out more
BOCH

Blue Owl Capital Holdings Portfolio holdings

AUM $372M
1-Year Est. Return 78.25%
This Fund
S&P 500
This Quarter Est. Return
+4.2%
1 Year Est. Return
+78.25%
3 Year Est. Return
+112.77%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$372M
AUM Growth
+$48.1M
Cap. Flow
+$80.2M
Cap. Flow %
21.56%
Top 10 Hldgs %
69.34%
Holding
99
New
19
Increased
13
Reduced
16
Closed
23

Top Buys

Rank Stock Value
1
AKTS
Aktis Oncology
AKTS
+$61.4M
2
MPLT
MapLight Therapeutics
MPLT
+$12.1M
3
ENGN icon
enGene Therapeutics
ENGN
+$9.4M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$8.7M
5
EYPT icon
EyePoint Inc
EYPT
+$7.78M

Top Sells

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$8.95M
2
PCOR icon
Procore
PCOR
+$6.86M
3
ROIV icon
Roivant Sciences
ROIV
+$5.71M
4
CGEM icon
Cullinan Oncology
CGEM
+$5.67M
5
CNTX icon
Context Therapeutics
CNTX
+$5.47M

Sector Composition

Rank Sector Weight
1 Healthcare 76.1%
2 Financials 13.79%
3 Consumer Discretionary 4.78%
4 Technology 2.41%
5 Real Estate 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKTS
1
Aktis Oncology
AKTS
$1.32B
$56.6M 15.2%
+3,161,348
New +$61.4M
LRMR icon
2
Larimar Therapeutics
LRMR
$416M
$32M 8.61%
7,120,007
+296,317
+4% +$1.18M
ENGN icon
3
enGene Therapeutics
ENGN
$122M
$30.1M 8.08%
4,416,353
+1,055,416
+31% +$9.4M
NCDL icon
4
Nuveen Churchill Direct Lending
NCDL
$599M
$27.3M 7.33%
2,143,626
– –
CGEM icon
5
Cullinan Oncology
CGEM
$1.05B
$27.1M 7.29%
1,909,764
-441,208
-19% -$5.67M
OBDC icon
6
Blue Owl Capital
OBDC
$5.35B
$22.6M 6.08%
2,045,070
– –
MPLT
7
MapLight Therapeutics
MPLT
$1.66B
$20.5M 5.49%
1,005,929
+678,871
+208% +$12.1M
CMPX icon
8
Compass Therapeutics
CMPX
$373M
$15.6M 4.18%
2,941,525
-525,000
-15% -$3.03M
CNTX icon
9
Context Therapeutics
CNTX
$56.4M
$13.3M 3.58%
5,089,015
-2,343,891
-32% -$5.47M
HLLY icon
10
Holley
HLLY
$314M
$13M 3.49%
4,236,888
+90,252
+2% +$342K
EYPT icon
11
EyePoint Inc
EYPT
$1.02B
$11.8M 3.16%
912,594
+520,000
+132% +$7.78M
CRVS icon
12
Corvus Pharmaceuticals
CRVS
$1.1B
$7.97M 2.14%
+545,000
New +$8.7M
CNDT icon
13
Conduent
CNDT
$230M
$6.45M 1.73%
5,036,595
+214,173
+4% +$326K
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.65B
$6.34M 1.7%
302,638
+90,000
+42% +$2.03M
AQST icon
15
Aquestive Therapeutics
AQST
$462M
$5.59M 1.5%
1,347,932
+822,932
+157% +$3.34M
RYTM icon
16
Rhythm Pharmaceuticals
RYTM
$7B
$5.34M 1.44%
+61,455
New +$5.98M
CMPS
17
Compass Pathways
CMPS
$1.52B
$5M 1.34%
904,504
+434,590
+92% +$2.92M
IMMX icon
18
Immix Biopharma
IMMX
$607M
$4.99M 1.34%
547,552
-438,688
-44% -$3.22M
IMA
19
ImageneBio Inc
IMA
$63.1M
$4.8M 1.29%
959,337
+135,552
+16% +$880K
CVEO icon
20
Civeo
CVEO
$379M
$4.78M 1.28%
180,475
-190,055
-51% -$5.1M
LENZ
21
LENZ Therapeutics
LENZ
$172M
$4.64M 1.25%
506,722
+356,722
+238% +$5.01M
ELDN icon
22
Eledon Pharmaceuticals
ELDN
$276M
$4.37M 1.18%
1,419,912
-510,000
-26% -$1.2M
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$4.33M 1.16%
215,000
-145,000
-40% -$2.34M
OVID icon
24
Ovid Therapeutics
OVID
$435M
$4.23M 1.14%
+1,904,666
New +$3.41M
PVLA
25
Palvella Therapeutics
PVLA
$1.98B
$3.9M 1.05%
31,259
-9,000
-22% -$939K
1
2 3 4

Similar funds

PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $372M AUM 50.62% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return

Blue Owl Capital Holdings's Q1 2026 Portfolio in Review

As of Q1 2026, Blue Owl Capital Holdings held 99 positions worth $372M, up 15% from $324M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Blue Owl Capital Holdings deployed $80.2M of net new capital in Q1 2026, opening 19 new positions and adding to 13 existing holdings. Its largest new stake was Aktis Oncology: 3,161,348 shares worth $56.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 64% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $5.67M trimmed.

  • Blue Owl Capital Holdings's largest Q1 2026 buy was Aktis Oncology: 3,161,348 shares worth $56.6M.
  • Blue Owl Capital Holdings added most to MapLight Therapeutics in Q1 2026, an estimated $12.1M increase.
  • Blue Owl Capital Holdings's biggest Q1 2026 reduction was Cullinan Oncology, cutting an estimated $5.67M.
  • Blue Owl Capital Holdings fully exited Repare Therapeutics in Q1 2026, selling an estimated $8.95M.
  • Blue Owl Capital Holdings's ten largest holdings make up 69% of its $372M portfolio in Q1 2026.
  • Blue Owl Capital Holdings opened 19 new positions and closed 23 in Q1 2026.
  • Blue Owl Capital Holdings's portfolio value rose 15% quarter-over-quarter to $372M.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.